Current Pharmaceutical Analysis publishes full-length/mini reviews and original research articles on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis and pharmacological research. The journal is essential to all involved in pharmaceutical, biochemical, biomedicine and clinical analysis.
Volumes 1-20 of Current Pharmaceutical Analysis, published by Bentham Science, can be accessed here: https://www.benthamscience.com/journal/cpa
This journal contains four sections:
Section A (Pharmaceutical Science): This section focuses on the discovery, development, evaluation, and regulation of medications and therapies. Its main goal is to enhance human health by developing new pharmaceutical products, refining drug delivery methods, and ensuring both the safety and effectiveness of treatments.
Section B (Toxicology and Pharmaceutics): This section focuses on the formulation, development, and toxicology response of drugs. It encompasses the design and testing of drug delivery systems to ensure optimal absorption, distribution, effectiveness and toxicity of medications in the body.
Section C (Pharmaceutical Biotechnology): This section focuses on the utilizing biological systems, processes, or organisms to create drugs and treatments. It encompasses the development of biopharmaceuticals, including vaccines, monoclonal antibodies, gene therapies, and bionanotechnology. Additionally, it involves the application of bioengineering methods to alter cells and microorganisms for therapeutic applications.
Section D (Drug Discovery): This section focuses on the identification, design, and development of new pharmaceutical compounds aimed at treating various diseases. It involves investigating novel chemical entities, natural substances, and biological molecules, utilizing methods such as high-throughput screening, molecular modeling, and structure-based drug design. The main goal is to discover safe, effective, and targeted treatments by comprehending disease mechanisms and refining lead compounds through preclinical evaluation.
